IVD China last week: Roche, Beckman Coulter and GE HealthCare, Fosun Insightec and Siemens Healthineers, MGI, BSBE

Roche Diagnostics’ Locally Manufactured cobas t 711 Coagulation Solution Approved in China

Roche Diagnostics announced the approval of its locally manufactured cobas t 711 Automated Coagulation Solution, marking a major step in the its “in China, for China” localization strategy. As Roche’s first domestically produced coagulation platform, the system introduces advanced automation features that significantly reduce manual handling while enhancing testing precision and emergency response efficiency.

The cobas t 711 will be produced at Roche’s Suzhou R&D and manufacturing hub under the same standards, materials, and processes as its global facilities, ensuring consistent quality while strengthening local supply and service capabilities. The approval underscores Roche’s commitment to bringing globally benchmarked diagnostic technologies closer to China’s clinical frontline.

Beckman Coulter and GE HealthCare Partner to Advance Alzheimer’s Diagnostics in China

On April 9, 2026, Beckman Coulter and GE HealthCare announced a strategic collaboration to advance localized research and clinical application for Alzheimer’s disease in China. By combining strengths in in vitro diagnostics and advanced medical imaging, the two companies aim to establish an integrated “blood screening + precision imaging” pathway tailored to the Chinese population.

The partnership seeks to move screening and diagnosis earlier in the care pathway while supporting the development of standardized approaches for neurodegenerative disease management. The initiative also underscores growing cross-disciplinary collaboration between nuclear medicine, imaging, and laboratory diagnostics to accelerate the translation of innovative technologies into practical clinical care.

Fosun Insightec and Siemens Healthineers Form Strategic Partnership on MR-Guided Focused Ultrasound

On April 9, Fosun Insightec and Siemens Healthineers signed a strategic cooperation agreement to advance the clinical adoption of MR-guided focused ultrasound (MRgFUS) for non-invasive treatment of neurological disorders. The collaboration integrates Fosun’s expertise in focused ultrasound commercialization and clinical application with Siemens Healthineers’ strengths in MRI technology.

The partnership will focus on joint market development, standardized clinical training, multi-center research, and ecosystem building around the “MRgFUS + MRI” integrated solution. The initiative aims to accelerate the translation of non-invasive therapeutic technologies into broader clinical practice and expand access to innovative treatment options for patients with conditions such as essential tremor and Parkinson’s disease.

MGI’s TaiM 4 Enables High-Throughput Single-Cell Hi-C for 3D Genomics Research

Gene Read has integrated Hi-C technology with MGI’s TaiM 4 single-cell droplet platform to develop a high-throughput microfluidic scHi-C workflow, bringing single-cell research into the era of three-dimensional genome analysis. By overcoming the averaging limitations of traditional bulk Hi-C, the solution enables researchers to capture chromatin structure heterogeneity at single-cell resolution across animal and plant tissues.

Combined with the Higashi machine-learning algorithm for sparse scHi-C data analysis, the platform supports deeper exploration of chromatin dynamics in development, differentiation, and disease. The advancement highlights how automated, scalable single-cell technologies are accelerating broader adoption of 3D genomics in life science research.

BSBE Launches GLA 1000 Automated Immunoassay Line for Small and Mid-Sized Laboratories

Beijing Strong Biotechnologies, Inc. (hereinafter referred to as BSBE) has introduced the GLA 1000 fully automated immunoassay workflow, designed specifically to address the automation needs of small and mid-sized laboratories and regional testing centers. With a compact footprint, intelligent workflow design, and stable performance, the system targets long-standing challenges in space constraints, efficiency, and quality control in primary and county-level healthcare settings.

The launch aligns with China’s broader push to strengthen grassroots medical capacity, standardize testing results, and advance smart hospital infrastructure. By delivering an integrated, cost-effective immunoassay solution, BSBE aims to accelerate laboratory automation and standardization across decentralized healthcare networks.